热门资讯> 正文
在第三阶段nex-z试验中发生严重不良事件后，intlia股价暴跌
2025-10-27 20:32
- Intellia Therapeutics (NASDAQ:NTLA) shares are down ~45% in premarket trading Monday after pausing dosing in two phase 3 trials for nexiguran ziclumeran (nex-z).
- The pause is due to a report of a patient who was hospitalized with Grade 4 liver transaminases and increased total bilirubin in the MAGNITUDE trial, which is evaluating the candidate in transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The other trial, MAGNITUDE-2, is in transthyretin amyloidosis with polyneuropathy (ATTR-PN).
- Enrollment for both trials is also on hold.
- Currently, 650 patients are enrolled in MAGNITUDE, and 47 patients in MAGNITUDE-2. More than 450 are estimated to have been dosed.
More on Intellia Therapeutics
- Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook
- Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis
- Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
- Intellia Therapeutics upgraded by Citizens JMP on HAE opportunity, shares rise 6%
- Cathie Wood's Ark Invest weekly recap: lifts stake in Bullish and Brera, trims Roku and Tempus AI
推荐文章
华盛早报 | 盘中暴涨20%！高通挑战英伟达；黄金跌破4000关口；小马智行、文远知行今起招股
美股机会日报 | 金价再度走弱！现失守4030美元；中美贸易争端缓和，纳指期货涨超1%
IBM、AMD双双大涨近8%！量子计算概念再起飞，下一个赢家是谁？
新股暗盘 | 滴普科技涨近50%，中签一手账面浮盈2660港元
新股暗盘 | 八马茶业涨79.00%，中签一手账面浮盈3950港元
美股波动中的稳健长跑选手：华尔街押注Pinterest(PINS.US)、Uber(UBER.US)与通用汽车(GM.US)
黄金火爆行情带热招聘市场 对冲基金、贸易商高薪争夺交易人才
迷雾中前行！美联储本周料将再度降息 内部分歧恐进一步加剧？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
